LTA and rheumatoid arthritis: Patient TN2 was undergoing treatment with soluble tumor necrosis factor-alpha (TNF-α)/lymphotoxin-alpha (LT-α) receptor for therapy of rheumatoid arthritis with Sjögren syndrome at the time of collection; IFI27 expression could be indirectly induced by this treatment.